Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Bio-Techne typically reports earnings before market open, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-05-06 | -$9.27 (-16.36%) | $11.56 (20.40%) | +$3.50 (+7.39%) | $4.59 (9.67%) |
| 2026-02-04 | +$4.04 (+6.25%) | $8.23 (12.73%) | -$2.81 (-4.09%) | $2.95 (4.30%) |
| 2025-11-05 | -$1.16 (-1.90%) | $6.92 (11.33%) | -$1.76 (-2.94%) | $3.86 (6.44%) |
| 2025-08-06 | -$4.77 (-8.73%) | $6.91 (12.64%) | +$0.28 (+0.56%) | $1.70 (3.41%) |
| 2025-05-07 | +$1.03 (+2.16%) | $3.62 (7.58%) | +$1.03 (+2.11%) | $3.52 (7.23%) |
| 2025-02-05 | +$2.70 (+3.72%) | $4.08 (5.62%) | -$0.24 (-0.32%) | $3.59 (4.77%) |
| 2024-10-30 | +$5.28 (+7.46%) | $5.51 (7.79%) | -$2.27 (-2.99%) | $2.67 (3.51%) |
| 2024-08-07 | -$7.46 (-9.51%) | $7.38 (9.42%) | +$2.41 (+3.40%) | $3.51 (4.95%) |
| Avg Abs Move | 7.01% | 10.94% | 2.97% | 5.53% |
Bio-Techne has exhibited significant volatility around earnings releases, with an average absolute Day 0 move of 7.01% and an average Day 0 range of 10.94%. The most recent report on May 6, 2026, triggered the largest reaction in the dataset—a 16.36% decline on Day 0 with a 20.40% intraday range—followed by a 7.39% rebound on Day +1. This dramatic swing likely reflected disappointment with results or guidance, followed by bargain-hunting or short-covering.
Looking across the eight-quarter history, Day 0 moves have been directionally mixed but consistently large, ranging from 1.90% to 16.36% in absolute terms. Day +1 follow-through averages 2.97%, suggesting initial reactions often moderate but don't fully reverse. The 10.94% average Day 0 range indicates substantial intraday volatility regardless of closing direction. Investors should prepare for a potentially significant move—likely in the 5–10% range based on historical patterns—with the direction hinging on whether TECH can beat the $0.46 estimate and provide encouraging commentary on fiscal 2027 trends.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 08/21/26 (DTE 10) |
| Expected Move | $0.09 (0.12%) |
| Expected Range | $72.05 to $72.22 |
| Implied Volatility | 14.02% |
The options market is pricing an expected move of just 0.12% through the August 21 expiration, far below the 7.01% average historical Day 0 move and even the 2.97% Day +1 average. This suggests options traders are either underpricing earnings volatility or the August expiration is too far removed from the August 12 earnings date to fully capture the event risk.
Part 3: What Analysts Are Saying
Analyst sentiment on Bio-Techne is cautiously neutral, with an average recommendation of 3.13 (between Hold and Buy) based on 15 analysts. The consensus breaks down to 2 Strong Buys, 0 Moderate Buys, 12 Holds, 0 Moderate Sells, and 1 Strong Sell—a distribution heavily weighted toward Hold ratings that reflects uncertainty about the near-term outlook.
The average price target of $69.61 implies 3.5% downside from the current price of $72.15, with estimates ranging from a low of $50.00 to a high of $73.00. The wide target range—spanning $23.00—underscores the divergence in analyst views on how quickly Bio-Techne can return to growth.
Sentiment has remained unchanged over the past month, with the rating distribution and average recommendation holding steady at 3.13. This stability suggests analysts are in wait-and-see mode ahead of earnings, with no recent catalysts prompting upgrades or downgrades. The modest implied downside from the consensus target, combined with the Hold-heavy rating distribution, indicates the Street is positioned defensively—expecting TECH to trade sideways until the company demonstrates clearer evidence of an earnings recovery.
Part 4: Technical Picture
Bio-Techne enters earnings with strong technical momentum, as the Barchart Technical Opinion currently shows a Buy signal at 88%, unchanged from last week but significantly improved from 56% one month ago. This strengthening reflects the stock's steady climb from the low-$60s in recent months to its current level of $72.15.
Timeframe Analysis:
- Short-term (100% Buy): Strong buy signal indicates robust near-term momentum heading into the earnings release
- Medium-term (100% Buy): Unanimous buy reading confirms the intermediate-term uptrend remains intact
- Long-term (50% Buy): Moderate buy signal suggests the longer-term trend is constructive but less emphatic than shorter timeframes
Trend Characteristics: The Strong strength combined with Average direction indicates a well-established uptrend with normal momentum characteristics—neither overheated nor losing steam.
The stock is trading above all key moving averages, including the 5-day ($72.09), 10-day ($72.08), 20-day ($71.92), 50-day ($65.62), 100-day ($58.94), and 200-day ($59.99). The tight clustering of short-term averages near the current price suggests consolidation at recent highs, while the significant distance above longer-term averages—particularly the $65.62 50-day and $59.99 200-day—confirms the strength of the multi-month rally.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $72.09 | 50-Day MA | $65.62 |
| 10-Day MA | $72.08 | 100-Day MA | $58.94 |
| 20-Day MA | $71.92 | 200-Day MA | $59.99 |
The $72.15 level represents a critical test, as the stock is trading just above its short-term moving averages and near the $73.00 high end of analyst price targets. The 50-day moving average at $65.62 would likely serve as initial support if earnings disappoint, while a beat could propel TECH toward new recovery highs. The overall technical setup is supportive but leaves little room for error—strong momentum provides a tailwind, but the stock has already priced in considerable optimism, making execution and guidance critical to sustaining the uptrend.